Background Spinal muscular atrophy (SMA) is one of the most common genetic causes of death in children affecting about one in 10,000 live births, while its prevalence is about 1–2 per 100,000 (live births). Recently, the European Commission (EU) approved a novel gene therapy based on the onasemnogen abeparvovec (Zolgensma) for the treatment of patients with SMA. In addition to drug treatment, it is essential that children with SMA apply self-care methods to maintain their health, monitor their weight and food intake, and use appropriate remedies. Self-care and co-production of health care services are crucial in the modern ecosystem, as they can improve survival and prevent hospitalizations. The aim of this work is to support healthcare pr...
Spinal Muscular Atrophy (SMA) is a genetic disorder characterized by weakness and muscle atrophy. Du...
Spinal muscular atrophy (SMA) is one of the most common autosomal recessive diseases, affecting apro...
Background: We report the clinical outcomes observed in our patients with SMA type 1 or 2 receiving ...
Background Spinal muscular atrophy (SMA) is one of the most common genetic causes of death in child...
Spinal muscular atrophy (SMA) is a hereditary disease characterized by progressive loss of -motoneur...
This thesis is focused on defining the specifics of nursing care for patients with disease spinal mu...
Introduction: Spinal muscular atrophy (SMA) is one of the most frequent autosomal recessive neuromus...
Background: Spinal muscular atrophy (SMA) is a rare neuromuscular disease characterized by degenerat...
Hereditary proximal spinal muscular atrophy (SMA) is a severe hereditary neuromuscular disorder, whi...
International audienceSpinal muscular atrophy type 1 (SMA-1) is a severe neurodegenerative disorder,...
Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder characterised by the degene...
Background: Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by muscle atroph...
Abstract Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized...
This thesis focuses on children with severe spinal muscular atrophy (SMA) and their families. Althou...
The scope of this dissertation focuses on issues related to the quality of life of children sufferin...
Spinal Muscular Atrophy (SMA) is a genetic disorder characterized by weakness and muscle atrophy. Du...
Spinal muscular atrophy (SMA) is one of the most common autosomal recessive diseases, affecting apro...
Background: We report the clinical outcomes observed in our patients with SMA type 1 or 2 receiving ...
Background Spinal muscular atrophy (SMA) is one of the most common genetic causes of death in child...
Spinal muscular atrophy (SMA) is a hereditary disease characterized by progressive loss of -motoneur...
This thesis is focused on defining the specifics of nursing care for patients with disease spinal mu...
Introduction: Spinal muscular atrophy (SMA) is one of the most frequent autosomal recessive neuromus...
Background: Spinal muscular atrophy (SMA) is a rare neuromuscular disease characterized by degenerat...
Hereditary proximal spinal muscular atrophy (SMA) is a severe hereditary neuromuscular disorder, whi...
International audienceSpinal muscular atrophy type 1 (SMA-1) is a severe neurodegenerative disorder,...
Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder characterised by the degene...
Background: Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by muscle atroph...
Abstract Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized...
This thesis focuses on children with severe spinal muscular atrophy (SMA) and their families. Althou...
The scope of this dissertation focuses on issues related to the quality of life of children sufferin...
Spinal Muscular Atrophy (SMA) is a genetic disorder characterized by weakness and muscle atrophy. Du...
Spinal muscular atrophy (SMA) is one of the most common autosomal recessive diseases, affecting apro...
Background: We report the clinical outcomes observed in our patients with SMA type 1 or 2 receiving ...